{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:42:26Z","timestamp":1763415746521,"version":"3.40.5"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_almed-2024-0053_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic hemolytic anemia and target organ damage. Pregnancy is associated with several forms of TMA, including preeclampsia (PE), HELLP syndrome, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). When HUS is secondary to a deregulation of the alternative complement pathway, it is known as atypical HUS (aHUS). Differential diagnosis is challenging, as these forms share clinical characteristics. However, early diagnosis is crucial for a specific treatment to be established and improve prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2024-0053_abs_002\">\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>We present the case of a 43 year-old primiparous woman admitted to hospital for an urgent C-section at 33 gestational weeks due to a diagnosis of severe preeclampsia and fetal distress. In the immediate postpartum, the patient developed acute liver failure and anuric renal failure in the context of the HELLP syndrome, anemia, thrombocytopenia, arterial hypertension (HTN) and neurological deficit. TMA study and differential diagnosis confirmed pregnancy-associated aHUS. Treatment with eculizumab was initiated, with good response and progressive improvement of clinical and analytical parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2024-0053_abs_003\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>aHUS is a rare multifactorial disease that used to be associated with high mortality rates before the advent of eculizumab. Due to challenging diagnosis, the clinical laboratory plays a major role in the differential diagnosis and management of the disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/almed-2024-0053","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T13:40:25Z","timestamp":1714052425000},"page":"340-344","source":"Crossref","is-referenced-by-count":1,"title":["Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis"],"prefix":"10.1515","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5447-3384","authenticated-orcid":false,"given":"Patricia","family":"Ramos Mayordomo","sequence":"first","affiliation":[{"name":"16918 Servicio de An\u00e1lisis Cl\u00ednicos, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Capilla D\u00edez","sequence":"additional","affiliation":[{"name":"16918 Servicio de An\u00e1lisis Cl\u00ednicos, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danay Areli","family":"Ticona Espinoza","sequence":"additional","affiliation":[{"name":"16918 Servicio de Nefrolog\u00eda, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Ver\u00f3nica","family":"Torres Jaramillo","sequence":"additional","affiliation":[{"name":"16918 Servicio de Nefrolog\u00eda, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Mart\u00ednez Tejeda","sequence":"additional","affiliation":[{"name":"16918 Servicio de Nefrolog\u00eda, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalia Gloria","family":"Ticona Espinoza","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Intensiva, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Colmenero Calleja","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Intensiva, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Fraile Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Intensiva, Hospital Universitario R\u00edo Hortega , Valladolid , Castilla y Le\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"2024090606221722387_j_almed-2024-0053_ref_001","doi-asserted-by":"crossref","unstructured":"Campistol, JM, Arias, M, Ariceta, G, Blasco, M, Espinosa, L, Espinosa, M, et al.. Documento de consenso: actualizaci\u00f3n en s\u00edndrome hemol\u00edtico ur\u00e9mico at\u00edpico: diagn\u00f3stico y tratamiento. Nefrolog\u00eda 2015;35:421\u201347. https:\/\/doi.org\/10.1016\/j.nefro.2015.07.005.","DOI":"10.1016\/j.nefro.2015.07.005"},{"key":"2024090606221722387_j_almed-2024-0053_ref_002","doi-asserted-by":"crossref","unstructured":"Fakhouri, F, Scully, M, Provot, F, Blasco, M, Coppo, P, Noris, M, et al.. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 2020;136:2103\u201317. https:\/\/doi.org\/10.1182\/blood.2020005221.","DOI":"10.1182\/blood.2020005221"},{"key":"2024090606221722387_j_almed-2024-0053_ref_003","unstructured":"Romero, MA, Or\u00f3s, D, Vigil-De Gracia, P, Fabre, E. Estados hipertensivos del embarazo, 7th ed. Barcelona, Spain: Elsevier; 2018."},{"key":"2024090606221722387_j_almed-2024-0053_ref_004","doi-asserted-by":"crossref","unstructured":"Arigita, M, Mart\u00ednez, GS. S\u00edndrome HELLP: controversias y pron\u00f3stico. Hipertens Riesgo Vasc 2020;37:147\u201351.","DOI":"10.1016\/j.hipert.2020.07.002"},{"key":"2024090606221722387_j_almed-2024-0053_ref_005","unstructured":"Sociedad Espa\u00f1ola de Ginecolog\u00eda y Obstetricia. Gu\u00eda de Asistencia Pr\u00e1ctica: Trastornos hipertensivos en la gestaci\u00f3n. Progresos Obstet Ginecol 2020;63:244\u201372."},{"key":"2024090606221722387_j_almed-2024-0053_ref_006","doi-asserted-by":"crossref","unstructured":"Bruel, A, Kavanagh, D, Noris, M, Delmas, Y, Wong, E, Bresin, E, et al.. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol 2017;12:1237\u201347. https:\/\/doi.org\/10.2215\/cjn.00280117.","DOI":"10.2215\/CJN.00280117"},{"key":"2024090606221722387_j_almed-2024-0053_ref_007","doi-asserted-by":"crossref","unstructured":"Chinchilla, KA, Vijayan, M, Taveras, B, Jim, B. Complement-mediated disorders in pregnancy. Adv Chron Kidney Dis 2020;27:155\u201364. https:\/\/doi.org\/10.1053\/j.ackd.2020.01.002.","DOI":"10.1053\/j.ackd.2020.01.002"},{"key":"2024090606221722387_j_almed-2024-0053_ref_008","doi-asserted-by":"crossref","unstructured":"Scully, M. How to evaluate and treat the spectrum of TMA syndromes in pregnancy. Hematology Am Soc Hematol Educ Program 2021;2021:545\u201351. https:\/\/doi.org\/10.1182\/hematology.2021000290.","DOI":"10.1182\/hematology.2021000290"},{"key":"2024090606221722387_j_almed-2024-0053_ref_009","doi-asserted-by":"crossref","unstructured":"Gaggl, M, Aigner, C, Csuka, D, Szil\u00e1gyi, A, Proh\u00e1szka, Z, Kain, R, et al.. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2018;29:1020\u20139. https:\/\/doi.org\/10.1681\/asn.2016090995.","DOI":"10.1681\/ASN.2016090995"},{"key":"2024090606221722387_j_almed-2024-0053_ref_010","doi-asserted-by":"crossref","unstructured":"Contreras, E, de la Rubia, J, del R\u00edo-Garma, J, D\u00edaz-Ricart, M, Garc\u00eda-Gala, JM, Lozano, M, et al.. Gu\u00eda diagn\u00f3stica y terap\u00e9utica de las microangiopat\u00edas tromb\u00f3ticas del Grupo Espa\u00f1ol de Af\u00e9resis. Med Clin 2015;144:331.e1\u201313. https:\/\/doi.org\/10.1016\/j.medcli.2014.09.013.","DOI":"10.1016\/j.medcli.2014.09.013"},{"key":"2024090606221722387_j_almed-2024-0053_ref_011","doi-asserted-by":"crossref","unstructured":"Fakhouri, F, Fr\u00e9meaux-Bacchi, V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543\u201353. https:\/\/doi.org\/10.1038\/s41581-021-00424-4.","DOI":"10.1038\/s41581-021-00424-4"},{"key":"2024090606221722387_j_almed-2024-0053_ref_012","doi-asserted-by":"crossref","unstructured":"Scully, M, Neave, L. Etiology and outcomes: thrombotic microangiopathies in pregnancy. Res Pract Thromb. Haemostasis 2023;7:100084. https:\/\/doi.org\/10.1016\/j.rpth.2023.100084.","DOI":"10.1016\/j.rpth.2023.100084"},{"key":"2024090606221722387_j_almed-2024-0053_ref_013","doi-asserted-by":"crossref","unstructured":"Fakhouri, F, Roumenina, L, Provot, F, Salle, M, Caillard, S, Couzi, L, et al.. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859\u201367. https:\/\/doi.org\/10.1681\/asn.2009070706.","DOI":"10.1681\/ASN.2009070706"},{"key":"2024090606221722387_j_almed-2024-0053_ref_014","doi-asserted-by":"crossref","unstructured":"Praga, M, Rodr\u00edguez de C\u00f3rdoba, S. Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney Int 2019;95:1298\u2013300. https:\/\/doi.org\/10.1016\/j.kint.2019.01.043.","DOI":"10.1016\/j.kint.2019.01.043"},{"key":"2024090606221722387_j_almed-2024-0053_ref_015","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico PT\/V1\/19112014: Informe de Posicionamiento Terap\u00e9utico de Eculizumab (Soliris\u00ae) en el S\u00edndrome Hemol\u00edtico Ur\u00e9mico at\u00edpico. Madrid: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios; 2014. https:\/\/www.aemps.gob.es\/ [Accessed 3 Sept 2023]."}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2024-0053\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2024-0053\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:25:30Z","timestamp":1725603930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2024-0053\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,6]]},"published-print":{"date-parts":[[2024,9,6]]}},"alternative-id":["10.1515\/almed-2024-0053"],"URL":"https:\/\/doi.org\/10.1515\/almed-2024-0053","relation":{},"ISSN":["2628-491X"],"issn-type":[{"type":"electronic","value":"2628-491X"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}